Taysha Gene Therapies Inc (TSHA)
2.37
-0.11
(-4.44%)
USD |
NASDAQ |
May 08, 16:00
2.36
-0.01
(-0.42%)
After-Hours: 16:08
Taysha Gene Therapies Enterprise Value: 360.37M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 360.37M |
| May 06, 2024 | 386.56M |
| May 03, 2024 | 377.20M |
| May 02, 2024 | 379.08M |
| May 01, 2024 | 349.15M |
| April 30, 2024 | 351.02M |
| April 29, 2024 | 354.76M |
| April 26, 2024 | 343.54M |
| April 25, 2024 | 326.71M |
| April 24, 2024 | 336.06M |
| April 23, 2024 | 369.72M |
| April 22, 2024 | 356.63M |
| April 19, 2024 | 321.10M |
| April 18, 2024 | 347.28M |
| April 17, 2024 | 354.76M |
| April 16, 2024 | 378.14M |
| April 15, 2024 | 394.04M |
| April 12, 2024 | 446.40M |
| April 11, 2024 | 498.77M |
| April 10, 2024 | 483.81M |
| April 09, 2024 | 450.14M |
| April 08, 2024 | 397.78M |
| April 05, 2024 | 397.78M |
| April 04, 2024 | 397.78M |
| April 03, 2024 | 405.26M |
| Date | Value |
|---|---|
| April 02, 2024 | 403.39M |
| April 01, 2024 | 427.70M |
| March 28, 2024 | 433.31M |
| March 27, 2024 | 489.42M |
| March 26, 2024 | 468.84M |
| March 25, 2024 | 468.84M |
| March 22, 2024 | 504.38M |
| March 21, 2024 | 476.32M |
| March 20, 2024 | 450.14M |
| March 19, 2024 | 317.36M |
| March 18, 2024 | 294.79M |
| March 15, 2024 | 326.58M |
| March 14, 2024 | 296.66M |
| March 13, 2024 | 319.10M |
| March 12, 2024 | 317.23M |
| March 11, 2024 | 334.05M |
| March 08, 2024 | 367.71M |
| March 07, 2024 | 367.71M |
| March 06, 2024 | 403.23M |
| March 05, 2024 | 420.06M |
| March 04, 2024 | 457.45M |
| March 01, 2024 | 500.45M |
| February 29, 2024 | 487.36M |
| February 28, 2024 | 390.14M |
| February 27, 2024 | 354.62M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-8.649M
Minimum
Mar 29 2023
947.67M
Maximum
Jan 20 2021
312.57M
Average
219.35M
Median
Jan 19 2022
Enterprise Value Benchmarks
| Aquestive Therapeutics Inc | 252.15M |
| Lifecore Biomedical Inc | -- |
| Relmada Therapeutics Inc | 18.94M |
| ACADIA Pharmaceuticals Inc | 2.405B |
| Cyclacel Pharmaceuticals Inc | -0.5964M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 47.74M |
| Revenue (Quarterly) | 3.604M |
| Total Expenses (Quarterly) | 19.40M |
| EPS Diluted (Quarterly) | 0.2554 |
| Earnings Yield | -56.31% |
| Normalized Earnings Yield | -33.78 |